⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27899869 | 0.81 | — | — | |
| SCHEMBL6629099 | 0.79 | — | — | |
| SCHEMBL322324 | 0.79 | — | — | |
| SCHEMBL18185932 | 0.77 | — | — | |
| SCHEMBL19551049 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL19550757 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL19550965 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL17559297 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL19551017 | 0.75 | ALDH1A1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL19550859 | 0.75 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-10 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4161519-A1 | PURINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20220227786-A1 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-21 | — | — | US | disclosed |
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-11 | — | — | US | disclosed |
| CN-106061963-B | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V生物科学股份有限公司 | 2019-10-22 | — | — | CN | disclosed |
| EP-3512857-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceutica NV (BE) | 2019-07-24 | — | — | EP | disclosed |
| CN-107531714-B | Imidazopyrazines ketone as PDE1 inhibitor | H.隆德贝克有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
| CN-109803658-A | Combined therapy comprising the Imidazopyrazines ketone for treating mental disease and/or cognitive disorder | H.隆德贝克有限公司 | 2019-05-24 | — | — | CN | disclosed |
| CN-109803653-A | Combined therapy including giving Imidazopyrazines ketone | H.隆德贝克有限公司 | 2019-05-24 | — | — | CN | disclosed |
| WO-2018050686-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
| EP-2802571-A1 | BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013105676-A1 | BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | WO | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |